Xact Kapitalforvaltning’s Acadia Pharmaceuticals ACAD Stock Holding History

Xact Kapitalforvaltning’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$986K	Hold	23,333	–	–	0.02%	508
2019 Q4	$998K	Buy	23,333 +3,401	+17%	+$148K	0.02%	616
2019 Q3	$717K	Hold	19,932	–	–	0.01%	722
2019 Q2	$533K	Hold	19,932	–	–	0.01%	875
2019 Q1	$535K	Hold	19,932	–	–	0.01%	880
2018 Q4	$322K	Buy	19,932 +3,900	+24%	+$75.7K	0.01%	1188
2018 Q3	$333K	Hold	16,032	–	–	0.01%	1290
2018 Q2	$245K	Buy	16,032 +700	+5%	+$12.5K	0.01%	1463
2018 Q1	$345K	Buy	15,332 +4,200	+38%	+$116K	0.01%	1125
2017 Q4	$335K	Buy	+11,132	New	+$356K	0.01%	874

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Xact Kapitalforvaltning's ACAD Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2020 at 23,333 shares worth $986K. The position accounts for 0.02% of the portfolio, ranked #508.

Xact Kapitalforvaltning first reported a position in ACAD in Q4 2017 and has held it in 10 quarters since. The position peaked at $998K in Q4 2019. 246 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

Xact Kapitalforvaltning held 23,333 shares of Acadia Pharmaceuticals worth $986K as of Q1 2020.
Xact Kapitalforvaltning left its Acadia Pharmaceuticals share count unchanged in Q1 2020.
Acadia Pharmaceuticals made up 0.02% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #508 holding.
Xact Kapitalforvaltning first reported a position in Acadia Pharmaceuticals in Q4 2017 and has held it in 10 quarters since.
Xact Kapitalforvaltning's Acadia Pharmaceuticals position peaked at $998K in Q4 2019.
246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.